Cytokine pathways and joint inflammation in rheumatoid arthritis.

Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that cannot be cured and that has substantial personal, social, and economic costs. The long-term prognosis is poor: 80 percent of affected patients are disabled after 20 years,1 and life expectancy is reduced by an average of 3 to 18 years.2 The medical cost of rheumatoid arthritis averages $5,919 per case per year in the United States3 and approximately £2,600 per case per year in the United Kingdom.4 Current slow-acting antirheumatic drugs have limited efficacy and many side effects. Moreover, they do not improve the long-term prognosis of rheumatoid arthritis. . . .

[1]  Richard W. Martin,et al.  A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL) , 2000 .

[2]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[3]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[4]  G. Burmester,et al.  The immunologic homunculus in rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[5]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[6]  J. V. van Meurs,et al.  Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. , 1999, Journal of immunology.

[7]  E. Yelin,et al.  An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. , 1999, Arthritis and rheumatism.

[8]  D. Furst,et al.  Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.

[9]  P. Robbins,et al.  Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. , 1999, Journal of immunology.

[10]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[11]  F. Breedveld,et al.  Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients , 1999 .

[12]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[13]  T. Kishimoto,et al.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. , 1998, Arthritis and rheumatism.

[14]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[15]  C. Ware,et al.  TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. , 1998, Journal of immunology.

[16]  P. Isomäki,et al.  Pro- and anti-inflammatory cytokines in rheumatoid arthritis. , 1997, Annals of medicine.

[17]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[18]  L. Davis,et al.  Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. , 1997, Arthritis and rheumatism.

[19]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[20]  P. Hart,et al.  Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. , 1996, Journal of immunology.

[21]  E. McIntosh,et al.  The cost of rheumatoid arthritis. , 1996, British journal of rheumatology.

[22]  G. Campion,et al.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. , 1996, Arthritis and rheumatism.

[23]  F. Breedveld,et al.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[24]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[25]  J. Bijlsma,et al.  Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. , 1996, Arthritis and rheumatism.

[26]  L. Joosten,et al.  Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .

[27]  A. Baldwin,et al.  Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Maruyama,et al.  Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. , 1995, The Journal of rheumatology.

[29]  W. Arend,et al.  Differential binding of human interleukin‐1 (IL‐1) receptor antagonist to natural and recombinant soluble and cellular IL‐1 type I receptors , 1995, European journal of immunology.

[30]  A. Duits,et al.  Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. , 1995, Annals of the rheumatic diseases.

[31]  M. Feldmann,et al.  Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. , 1995, European cytokine network.

[32]  G. Kingsley,et al.  The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. , 1995, British journal of rheumatology.

[33]  G. Kingsley,et al.  Peripheral blood and synovial fluid monocyte expression of interleukin 1 alpha and 1 beta during active rheumatoid arthritis. , 1995, The Journal of rheumatology.

[34]  J. Dayer,et al.  Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .

[35]  J. Banchereau,et al.  Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. , 1995, Journal of immunology.

[36]  R. Strieter,et al.  Cytokines in rheumatoid arthritis. , 1995, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[37]  A. Dam,et al.  Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: Routes and intermediate signals , 1994, Psychoneuroendocrinology.

[38]  C. Dinarello,et al.  The interleuldn-1 family: 10 years of discovery’ , 2004 .

[39]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[40]  R. Bast,et al.  Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.

[41]  M. Feldmann,et al.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis , 1994, The Journal of experimental medicine.

[42]  G. Passeri,et al.  Interleukin-11: a new cytokine critical for osteoclast development. , 1994, The Journal of clinical investigation.

[43]  S. Marsters,et al.  Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. , 1994, Journal of immunology.

[44]  P. Wooley,et al.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. , 1993, Journal of immunology.

[45]  L. Tartaglia,et al.  Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. , 1993, Journal of immunology.

[46]  Y. Nagai,et al.  The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells , 1993, Clinical and experimental immunology.

[47]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[48]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[49]  M. Gayle,et al.  Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Mak,et al.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection , 1993, Cell.

[51]  D. Willoughby,et al.  Cartilage degradation by polymorphonuclear leucocytes: in vitro assessment of the pathogenic mechanisms. , 1993, Annals of the rheumatic diseases.

[52]  J. Dayer,et al.  Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. , 1993, European cytokine network.

[53]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Cope,et al.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. , 1992, Arthritis and rheumatism.

[55]  J. Lanchbury.  The HLA association with rheumatoid arthritis. , 1992, Clinical and experimental rheumatology.

[56]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[57]  R. Thompson,et al.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. , 1991, Immunology today (Amsterdam. Regular ed.).

[58]  M. Turner,et al.  Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α , 1991, European journal of immunology.

[59]  K. Huebner,et al.  A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.

[60]  J. Taurog,et al.  Mechanisms of disruption of the articular cartilage surface in inflammation. Neutrophil elastase increases availability of collagen type II epitopes for binding with antibody on the surface of articular cartilage. , 1991, The Journal of clinical investigation.

[61]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[62]  J. Chin,et al.  Role of cytokines in inflammatory synovitis , 1990 .

[63]  M. Lark,et al.  Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. , 1990, The Journal of biological chemistry.

[64]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Snick,et al.  Interleukin-6: an overview. , 1990, Annual review of immunology.

[66]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[67]  C. March,et al.  cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. , 1988, Science.

[68]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[69]  D. Symmons,et al.  LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARS , 1987, The Lancet.

[70]  B Henderson,et al.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[71]  T. Pincus,et al.  Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. , 1986, The Journal of rheumatology.

[72]  L. Chess,et al.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.